HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeted treatments to improve stem cell outcome: old and new drugs.

Abstract
Thalidomide, lenalidomide and bortezomib have been approved for the treatment of relapsed or refractory multiple myeloma in the recent years. These agents are now being increasingly integrated into therapeutic regimens for newly diagnosed patients. First data are available on the promising activity of these novel agents in induction therapy, as well as maintenance treatment to improve outcome after stem cell transplantation. Whether these early results will lead to prolonged overall survival and thereby ultimately redefine the role of stem cell transplantation in first-line treatment of multiple myeloma will be one of the most important questions to be answered in the coming years. Bone Marrow Transplantation (2007) 40, 1129-1137; doi:10.1038/sj.bmt.1705829; published online 3 September 2007.
AuthorsM S Raab, I Breitkreutz, K C Anderson
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 40 Issue 12 Pg. 1129-37 (Dec 2007) ISSN: 0268-3369 [Print] England
PMID17768392 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Lenalidomide
Topics
  • Antineoplastic Agents (therapeutic use)
  • Boronic Acids
  • Bortezomib
  • Drug Delivery Systems (methods, trends)
  • Hematopoietic Stem Cell Transplantation (methods)
  • Humans
  • Lenalidomide
  • Multiple Myeloma (therapy)
  • Pyrazines
  • Thalidomide (analogs & derivatives)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: